Cerebrovascular Accident Clinical Trial
Official title:
Field Administration of Stroke Therapy-Magnesium Trial: A Randomized, Double-Blind, Placebo Controlled Trial of Neuroprotective Magnesium Sulfate Therapy for Acute Stroke Initiated Within 2 Hours of Onset by Paramedics in the Field
The goal of this study is to evaluate the effectiveness and safety of field-initiated magnesium sulfate in improving the long-term functional outcome of patients with acute stroke.
Stroke is the third leading cause of death and the leading cause of adult disability in the
United States. Each year, more than 750,000 Americans suffer a symptomatic stroke.
Currently, tissue plasminogen activator (rt-PA) is the only approved treatment for acute
ischemic stroke; however, its usefulness is limited because most patients cannot reach
medical attention within the necessary 3-hour time window. In addition, rt-PA cannot be
given in the field because it is contraindicated for treatment of patients with brain
hemorrhage.
The purpose of this multi-center, randomized, double-blind trial is to demonstrate that
paramedic initiation of the neuroprotective agent magnesium sulfate in the field is an
effective and safe treatment for acute stroke. This study will analyze magnesium sulfate, an
experimental therapy for stroke, versus placebo among ambulance-transported patients with
acute stroke. This trial will also demonstrate that paramedics can safely, effectively, and
rapidly start neuroprotective therapies for stroke.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05477238 -
Oxygen Consumption in Post-stroke Patients During Various Walking Activities Compared to Healthy Controls
|
N/A | |
Completed |
NCT00046293 -
ReoPro and Retavase to Treat Acute Stroke
|
Phase 2 | |
Completed |
NCT04584645 -
A Digital Flu Intervention for People With Cardiovascular Conditions
|
N/A | |
Completed |
NCT01116544 -
Treatment of Chronic Stroke With AMES + EMG Biofeedback
|
N/A | |
Withdrawn |
NCT04991038 -
Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients
|
N/A | |
Active, not recruiting |
NCT02563886 -
Electrically Assisted Movement Therapy
|
N/A | |
Recruiting |
NCT02446730 -
Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome
|
Phase 4 | |
Completed |
NCT02141932 -
Pocket-size Cardiovascular Ultrasound in Stroke
|
N/A | |
Completed |
NCT01915368 -
Determining Optimal Post-Stroke Exercise (DOSE)
|
N/A | |
Recruiting |
NCT02557737 -
Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Upper Extremities
|
Phase 3 | |
Recruiting |
NCT01769326 -
Influence of Timing on Motor Learning
|
N/A | |
Terminated |
NCT01705353 -
The Role of HMGB-1 in Chronic Stroke
|
N/A | |
Completed |
NCT01656876 -
The Effects of Mirror Therapy on Upper Extremity in Stroke Patients
|
N/A | |
Completed |
NCT01423201 -
Transient Ischemic Attack (TIA) Triage and Evaluation of Stroke Risk
|
||
Completed |
NCT01182818 -
Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease
|
N/A | |
Completed |
NCT00542256 -
tDCS and Physical Therapy in Stroke
|
N/A | |
Withdrawn |
NCT00573092 -
Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs
|
N/A | |
Completed |
NCT00377689 -
Evaluation of an Intervention Program Targeted at Improving Balance and Functional Skills After Stroke
|
Phase 2 | |
Recruiting |
NCT00166751 -
Sonographic Assessment of Laryngeal Elevation
|
N/A | |
Terminated |
NCT00120289 -
Niacin Plus Statin to Prevent Vascular Events
|
Phase 3 |